替加環(huán)素對多重耐藥鮑曼不動桿菌的體外抗菌活性和防耐藥突變研究
發(fā)布時間：2018-07-14 10:11
【摘要】：目的：測定替加環(huán)素對多重耐藥鮑曼不動桿菌（MDR-AB）的最低抑菌濃度（MIC），并在此基礎上應用Monte-Carlo模擬進行PK/PD研究，評價不同劑量替加環(huán)素治療MDR-AB肺炎效果。評價替加環(huán)素聯(lián)合多粘菌素E或舒巴坦對MDR-AB的抗菌效應；研究質(zhì)子泵抑制劑（PPIs）對替加環(huán)素體外抗菌活性的影響�；谀退幫蛔冞x擇窗（MSW）理論，測定替加環(huán)素單用及聯(lián)合多粘菌素E或舒巴坦限制MDR-AB耐藥發(fā)生的能力，初步探究MDR-AB對替加環(huán)素的耐藥機制。 方法：（1）采用瓊脂平板二倍稀釋法測定替加環(huán)素對135株MDR-AB的MIC，并結合410例肺炎患者的替加環(huán)素藥代學數(shù)據(jù)，通過Monte-Carlo模擬計算不同劑量替加環(huán)素時AUC/MIC值分布，再根據(jù)預設折點計算治療MDR-AB肺炎的累積反應分數(shù)（CFR）。（2）參照棋盤法設計，采用微量肉湯稀釋法測定替加環(huán)素與多粘菌素E、舒巴坦對70株MDR-AB的聯(lián)合MIC，計算聯(lián)合抑菌指數(shù)（FICI）并判定聯(lián)合效應。（3）采用瓊脂平板二倍稀釋法測定替加環(huán)素單藥及聯(lián)合PPIs對6種臨床常見分離菌的MIC；采用菌落計數(shù)法測定替加環(huán)素單藥及聯(lián)合PPIs的體外殺菌曲線。（4）采用瓊脂平板二倍稀釋法測定替加環(huán)素、多粘菌素E及舒巴坦對30株MDR-AB的MIC和防耐藥突變濃度（MPC），計算選擇指數(shù)（SI=MPC/MIC）；隨機選取9株細菌，測定替加環(huán)素聯(lián)合用藥的MPC，計算SI。（5）測定替加環(huán)素單藥及聯(lián)合碳酰氰間氯苯腙（CCCP）對體外篩選耐藥突變菌株的MIC；利用RT-PCR技術測定耐藥突變菌株外排泵基因AdeB和AdeJ的相對表達情況。 結果：（1）135株MDR-AB中97%的菌株對替加環(huán)素敏感，3%中介，未發(fā)現(xiàn)耐藥菌株。以CFR≥90%為預設折點，Monte-Carlo模擬分析表明，推薦給藥劑量（50mg/Lq12h）的CFR為61.62%，低于折點值；給藥劑量為100mg q12h時，CFR為89.86%，接近折點值。（2）聯(lián)合用藥后，替加環(huán)素對MDR-AB的MIC50顯著下降，70株MDR-AB的FICI分布為：與多粘菌素E聯(lián)用時，F(xiàn)ICI≤0.5占4.3%，0.5＜FICI＜1占20%，F(xiàn)ICI=1占11.4%，1＜FICI≤2占64.3%，F(xiàn)ICI＞2為0；與舒巴坦聯(lián)用時，F(xiàn)ICI≤0.5占10%，0.5＜FICI＜1占54.3%，F(xiàn)ICI=1占25.7%，1＜FICI≤2占10%，F(xiàn)ICI＞2為0。（3）培養(yǎng)基中加入5-10mg/L的PPIs會使細菌對替加環(huán)素MIC50增高0-2倍；加入50mg/L PPIs，細菌MIC50增加4-＞128倍。加入PPIs后的殺菌曲線均位于單藥殺菌曲線上方，表明各時間點菌落計數(shù)較單藥出現(xiàn)不同程度增高。（4）替加環(huán)素對MDR-AB的MPC值為4-32mg/L，SI范圍為4-64；聯(lián)合4mg/L多粘菌素E后SI下降2-4倍，聯(lián)合8mg/L后SI下降4-8倍；聯(lián)合32mg/L舒巴坦后SI下降2-8倍；聯(lián)合64mg/L舒巴坦SI后下降4-64倍。（5）聯(lián)合CCCP后，原菌株MIC并無變化，除AB10號突變菌株外，，其他4株MIC下降了16-128倍。5株耐藥突變菌株外排泵基因AdeJ的表達量較原菌株相比均未見明顯增高，除AB10號突變菌株外，其余突變菌外排泵基因AdeB表達量增高2倍以上。 結論：（1）雖然MDR-AB對替加環(huán)素敏感率較高，但Monte-carlo模擬分析表明推薦給藥劑量對MDR-AB肺炎的療效并不理想。（2）替加環(huán)素與多粘菌素E聯(lián)用對MDR-AB以無關作用為主，與舒巴坦聯(lián)用以部分協(xié)同為主。（3）培養(yǎng)基中加入PPIs會影響替加環(huán)素的體外抗菌活性。（4）替加環(huán)素、多粘菌素E及舒巴坦MPC較高、MSW寬，單用藥易致細菌耐藥發(fā)生；聯(lián)合用藥可有效限制耐藥發(fā)生。（5）突變菌株對替加環(huán)素的耐藥機制主要為外排泵基因AdeABC過度表達。
[Abstract]:Objective: to determine the minimum inhibitory concentration (MIC) of tegacycline on multidrug resistant Acinetobacter Bauman (MDR-AB), and to evaluate the effect of different doses of tegicycline in the treatment of MDR-AB pneumonia by Monte-Carlo simulation on the basis of PK/PD, and evaluate the antibacterial effect of tegacycline combined with polymyxin E or sulbactam on MDR-AB. The effect of pump inhibitor (PPIs) on the antiseptic activity of tegagin in vitro. Based on the resistance mutation selection window (MSW) theory, the ability of tegagin single use and combined polymyxin E or sulbactam to restrict the occurrence of MDR-AB resistance was determined, and the mechanism of MDR-AB resistance to tegagin was preliminarily explored.
Methods: (1) the two times dilution method of agar plate was used to determine the MIC of tegagin on 135 strains of MDR-AB and the data of tegadin in 410 patients with pneumonia. The distribution of AUC/MIC value at different doses of tegagin was simulated by Monte-Carlo, and the cumulative reaction fraction (CFR) for the treatment of MDR-AB pneumonia was calculated according to the presupposed fold point. (2) reference Chessboard method, tegagarin and polymyxin E were measured with micro broth dilution method, combined MIC of 70 strains of MDR-AB by Shubatan, combined bacteriostasis index (FICI) was calculated and combined effect was determined. (3) MIC of tigocycline single drug and combined PPIs against 6 clinical common isolates were measured by agar plate two times dilution method; colony counting method was used. The bactericidal curves of tegagin single drug and combined PPIs were measured in vitro. (4) two times dilution method of agar plate was used to determine the MIC and anti drug resistance mutation concentration (MPC) of 30 strains of MDR-AB and the selection index (SI=MPC/MIC), 9 strains of bacteria were selected and MPC of tegicycline combined use was measured, and SI. (5) was calculated. The MIC of resistant mutant strains was screened by CN and CCCP, and the relative expression of AdeB and AdeJ of the efflux pump gene of the mutant strain was determined by RT-PCR technique.
Results: (1) 97% of the 135 strains of MDR-AB were sensitive to tigocyclin, 3% medium, and no drug resistant strains were found. CFR > 90% as a preset point. Monte-Carlo simulation analysis showed that the recommended dosage (50mg/Lq12h) CFR was 61.62%, lower than the fold value; when the dosage was 100mg q12h, CFR was 89.86%, close to the fold value. (2) after the combination, TIG. The MIC50 of MDR-AB decreased significantly, and the FICI distribution of 70 strains of MDR-AB was as follows: when combined with polymyxin E, FICI < 0.5 was 4.3%, 0.5 < FICI < 1, 11.4%, 1 < FICI < 2, 64.3%, FICI > 2 as 0. The addition of 5-10mg/L to PPIs in the nutrient group increased the bacteria to tegatin MIC50 0-2 times; adding 50mg/L PPIs, the bacterial MIC50 increased by 4- > 128 times. The bactericidal curves after adding PPIs were above the bactericidal curve of the single drug, indicating that the colony count at each time point was higher than that of the single drug. (4) the MPC value of tegocyclin to MDR-AB was 4-32mg/L, SI. The range was 4-64, SI decreased 2-4 times after combined 4mg/L polymyxin E, SI decreased 4-8 times after combined 8mg/L, SI decreased by 2-8 times after combined with sulbactam and 4-64 times after SI. (5) after CCCP, the original strain MIC was not changed. Except for AB10 number mutant strain, his 4 strains dropped 16-128 times the resistant mutant strain of mutant strain. Compared with the original strain, the expression of the pump gene AdeJ was not significantly higher than that of the original strain. In addition to the mutant strain AB10, the expression of the pump gene AdeB of the other mutant strains increased by more than 2 times.
Conclusions: (1) although the sensitivity of MDR-AB to tegicycline is high, Monte-carlo simulation analysis shows that the recommended dosage is not ideal for the efficacy of MDR-AB pneumonia. (2) the combination of tegocycline and polymyxin E is independent of MDR-AB, and combined with sulbactam in combination with partial synergy. (3) the addition of PPIs in the medium affects tegocycline. In vitro antibacterial activity. (4) tegatocin, polymyxin E and sulbactam MPC are higher, MSW is wide, and single drug is easy to cause bacterial resistance. (5) the resistance mechanism of the mutant strain to tegagin is mainly overexpression of the outer row pump gene AdeABC.
【學位授予單位】：中國人民解放軍醫(yī)學院
【學位級別】：碩士
【學位授予年份】：2014
【分類號】：R96
本文編號：2121317
[Abstract]:Objective: to determine the minimum inhibitory concentration (MIC) of tegacycline on multidrug resistant Acinetobacter Bauman (MDR-AB), and to evaluate the effect of different doses of tegicycline in the treatment of MDR-AB pneumonia by Monte-Carlo simulation on the basis of PK/PD, and evaluate the antibacterial effect of tegacycline combined with polymyxin E or sulbactam on MDR-AB. The effect of pump inhibitor (PPIs) on the antiseptic activity of tegagin in vitro. Based on the resistance mutation selection window (MSW) theory, the ability of tegagin single use and combined polymyxin E or sulbactam to restrict the occurrence of MDR-AB resistance was determined, and the mechanism of MDR-AB resistance to tegagin was preliminarily explored.
Methods: (1) the two times dilution method of agar plate was used to determine the MIC of tegagin on 135 strains of MDR-AB and the data of tegadin in 410 patients with pneumonia. The distribution of AUC/MIC value at different doses of tegagin was simulated by Monte-Carlo, and the cumulative reaction fraction (CFR) for the treatment of MDR-AB pneumonia was calculated according to the presupposed fold point. (2) reference Chessboard method, tegagarin and polymyxin E were measured with micro broth dilution method, combined MIC of 70 strains of MDR-AB by Shubatan, combined bacteriostasis index (FICI) was calculated and combined effect was determined. (3) MIC of tigocycline single drug and combined PPIs against 6 clinical common isolates were measured by agar plate two times dilution method; colony counting method was used. The bactericidal curves of tegagin single drug and combined PPIs were measured in vitro. (4) two times dilution method of agar plate was used to determine the MIC and anti drug resistance mutation concentration (MPC) of 30 strains of MDR-AB and the selection index (SI=MPC/MIC), 9 strains of bacteria were selected and MPC of tegicycline combined use was measured, and SI. (5) was calculated. The MIC of resistant mutant strains was screened by CN and CCCP, and the relative expression of AdeB and AdeJ of the efflux pump gene of the mutant strain was determined by RT-PCR technique.
Results: (1) 97% of the 135 strains of MDR-AB were sensitive to tigocyclin, 3% medium, and no drug resistant strains were found. CFR > 90% as a preset point. Monte-Carlo simulation analysis showed that the recommended dosage (50mg/Lq12h) CFR was 61.62%, lower than the fold value; when the dosage was 100mg q12h, CFR was 89.86%, close to the fold value. (2) after the combination, TIG. The MIC50 of MDR-AB decreased significantly, and the FICI distribution of 70 strains of MDR-AB was as follows: when combined with polymyxin E, FICI < 0.5 was 4.3%, 0.5 < FICI < 1, 11.4%, 1 < FICI < 2, 64.3%, FICI > 2 as 0. The addition of 5-10mg/L to PPIs in the nutrient group increased the bacteria to tegatin MIC50 0-2 times; adding 50mg/L PPIs, the bacterial MIC50 increased by 4- > 128 times. The bactericidal curves after adding PPIs were above the bactericidal curve of the single drug, indicating that the colony count at each time point was higher than that of the single drug. (4) the MPC value of tegocyclin to MDR-AB was 4-32mg/L, SI. The range was 4-64, SI decreased 2-4 times after combined 4mg/L polymyxin E, SI decreased 4-8 times after combined 8mg/L, SI decreased by 2-8 times after combined with sulbactam and 4-64 times after SI. (5) after CCCP, the original strain MIC was not changed. Except for AB10 number mutant strain, his 4 strains dropped 16-128 times the resistant mutant strain of mutant strain. Compared with the original strain, the expression of the pump gene AdeJ was not significantly higher than that of the original strain. In addition to the mutant strain AB10, the expression of the pump gene AdeB of the other mutant strains increased by more than 2 times.
Conclusions: (1) although the sensitivity of MDR-AB to tegicycline is high, Monte-carlo simulation analysis shows that the recommended dosage is not ideal for the efficacy of MDR-AB pneumonia. (2) the combination of tegocycline and polymyxin E is independent of MDR-AB, and combined with sulbactam in combination with partial synergy. (3) the addition of PPIs in the medium affects tegocycline. In vitro antibacterial activity. (4) tegatocin, polymyxin E and sulbactam MPC are higher, MSW is wide, and single drug is easy to cause bacterial resistance. (5) the resistance mechanism of the mutant strain to tegagin is mainly overexpression of the outer row pump gene AdeABC.
【學位授予單位】：中國人民解放軍醫(yī)學院
【學位級別】：碩士
【學位授予年份】：2014
【分類號】：R96
【參考文獻】
相關期刊論文 前3條
1 崔俊昌;抗菌藥物防突變濃度及其臨床意義[J];國外醫(yī)學(呼吸系統(tǒng)分冊);2003年06期
2 饒勇,曾振靈,陳杖榴;抗生素耐藥性的主動外排機制[J];國外醫(yī)藥(抗生素分冊);2002年03期
3 田鈴;嵇保中;劉曙雯;金鳳;高潔;;甲基轉移酶的功能與分類[J];生命的化學;2007年05期
本文編號：2121317
本文鏈接：http://www.lk138.cn/yixuelunwen/yiyaoxuelunwen/2121317.html
最近更新
教材專著
